Pipeline Agents Aim to
Address Unmet Needs of Advanced Patients in Limiting OFF Time
Most of the late-stage
pipeline agents are set to meet the needs of advanced patients, with five
agents expected to launch during the forecast period (Rytary, CVT-301,
opicapone, safinamide, and tozadenant); three of them will be used almost
exclusively in advanced patients (CVT-301, opicapone, tozadenant). Additional
launches of currently marketed drugs in specific markets will include Duodopa
in the US and Japan; Neupro in the US, Japan, and Brazil; Nouriast in the US,
5EU, and Japan; Apokyn in Japan; and Requip XL in Japan. GlobalData believes
that Newron's safinamide, Impax's Rytary for early and advanced patients and
Civitas' CVT-301 for advanced patients are most promising.
Newron and Zambon’s
dual-mechanism MAO-B and glutamate release inhibitor, safinamide, is expected
to be a strong competitor in the Parkinson's disease market for early and
advanced-stage Parkinson's disease patients, with forecast global sales of
$423.2m in 2022. Safinamide is likely to be prescribed over MAO-B inhibitor
Azilect (Teva/Lundbeck), due to novel activity as a glutamate release inhibitor.
Impax's Rytary is a
slow-release formulation of levodopa that has shown good efficacy and
improvements in QOL during clinical trials. Impax is currently finalizing
regulatory issues and seeking a new partner for Rytary's ongoing clinical
development. In all, the pipeline candidate is forecast to generate sales of
$205.3m by 2022, following a late 2014 launch in the US.
Civitas' CVT-301 is a
novel reformulation of levodopa and the first inhaled device for Parkinson's
disease. It is expected to be the first widely used emergency therapy to meet a
key unmet need in wearing-off. Forecast to garner strong sales of $460.1m in
2022, Civitas will likely require partnership for the marketing and sales of
its product.
UCB/Biotie's tozadenant is
expected to be the second-to-market A2A antagonist that will be used to treat
advanced patients, despite limited efficacy in Phase II trials. As a strong
player in the Parkinson's disease market, owing to UCB's longstanding presence
in the US market and extensive portfolio for Parkinson's disease, tozadenant is
forecast to generate global sales of $29.9m in 2022.
Key Questions Answered in this Report
- According to KOLs, what are the most important unmet needs in PD? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2022?
- With five new product launches, three of which address the needs of advanced stage patients, which products are forecast to generate the highest sales over 2012-2022?
- What corporate strategies have been employed for recent product launches? What opportunities remain for new entrants?
- An aging population is expected to increase prevalence of PD in all markets from 2012-2022. How will epidemiological changes impact the growth of the future PD market?
- What governmental developments are likely to affect reimbursement and generic erosion of PD drugs? What type of impact will this have on the markets covered over the forecast period?
Spanning
Over 327 pages, “PharmaPoint: Parkinson’s Disease - Global Drug
Forecast and Market Analysis to 2022”
report
covering the Disease Overview, Epidemiology, Disease Management, Competitive
Assessment, Opportunity and Unmet Need, Pipeline Assessment, Current and Future
Players, Market Outlook, Appendix. The report covered companies are - Merck,
Roche, AbbVie, UCB, GlaxoSmithKline, Novartis, Orion, Newron, Civitas, Impax,
Lundbeck
See Table of contents & Purchase this
publication at: - http://mrr.cm/ZQd
No comments:
Post a Comment
Note: only a member of this blog may post a comment.